Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) was the recipient of a large drop in short interest in the month of December. As of December 29th, there was short interest totalling 1,302,795 shares, a drop of 39.6% from the December 15th total of 2,157,383 shares. Based on an average daily volume of 730,078 shares, the short-interest ratio is currently 1.8 days. Approximately 1.5% of the shares of the stock are sold short.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors purchased a new position in Catalyst Pharmaceuticals during the second quarter valued at $111,000. New York State Common Retirement Fund purchased a new position in Catalyst Pharmaceuticals during the second quarter valued at $114,000. SG Americas Securities LLC purchased a new position in Catalyst Pharmaceuticals during the third quarter valued at $144,000. State of Wisconsin Investment Board purchased a new position in Catalyst Pharmaceuticals during the second quarter valued at $149,000. Finally, The Manufacturers Life Insurance Company grew its stake in Catalyst Pharmaceuticals by 1,861.3% during the second quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 59,896 shares in the last quarter. 34.75% of the stock is owned by institutional investors.

Several analysts have recently commented on the stock. Piper Jaffray Companies set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 1st. SunTrust Banks reaffirmed a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Wednesday, November 29th. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st. Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $6.25.

Catalyst Pharmaceuticals (CPRX) opened at $3.92 on Monday. The firm has a market cap of $338.16, a price-to-earnings ratio of -18.67 and a beta of 1.68. Catalyst Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $4.51.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. analysts predict that Catalyst Pharmaceuticals will post -0.22 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2018/01/15/catalyst-pharmaceuticals-inc-cprx-sees-significant-decline-in-short-interest.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.